Watching Silexion Therapeutics Corp? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsReg FD DisclosureItem 7.01 · 8-KLOW RiskPositive
Silexion Therapeutics Corp
silexion.comFiled: Jul 29, 2026Modiin, Judea and SamariaCIK: 0002022416Health Care
AI Executive Summary
AI-powered analysis of 8-K filing content
Silexion Therapeutics announced the initiation of a Phase 2/3 clinical trial for SIL204 targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on July 29, 2026. This milestone advances the company's oncology portfolio in an area of high unmet medical need and may strengthen investor confidence.
Key Takeaways
Phase 2/3 clinical trial for SIL204 has been successfully initiated for locally advanced pancreatic cancer treatment
Trial is being conducted at Tel Aviv Sourasky Medical Center, indicating international clinical development infrastructure
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJul 29, 2026
Item7.01
CategoryReg FD Disclosure
CIK0002022416
Accession #001-42253
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory
What This Means
The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.